MAP2K7 and non-small cell lung carcinoma: In fact, we have designed a similar murine lung cancer co-clinical trial as previously reported [11], to combine metformin and MEK inhibition in KRAS-driven lung cancer GEM models with different concomitant mutations, and plan to incorporate the data into a clinical trial using the same combination for patients with KRAS-mutant NSCLC.